{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:31:08Z","timestamp":1768710668303,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Evidence-Based Complementary and Alternative Medicine"],"published-print":{"date-parts":[[2021,11,22]]},"abstract":"<jats:p>Objective. To observe the clinical effects of Jiawei Danggui Beimu Kushen pills in treating prostate cancer and their influence on the expression of serum prostate specific antigen. Methods. A total of 234 prostate cancer patients were selected and randomly divided into observation group and control group, with 117 cases in each group. The control group was given oral bicalutamide tablets, while the observation group was treated with Jiawei Danggui Beimu Kushen pills on the basis of the control group. The treatment efficacy, IPSS score, TCM syndrome score, VAS score, quality-of-life score, and immune function of the two groups were compared before and after treatment. The serum PSA and f-PSA levels of patients before treatment and after 30 days, 90 days, and 180 days of treatment in the two groups were compared. The five-year cumulative survival rate and the incidence of adverse reactions were compared between the two groups. Results. After treatment, the total effective rate of the observation group was 88.03% (103\/117), which was higher than that of the control group 69.23% (81\/117); the difference was statistically significant (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>0.05<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>). After treatment, the IPSS score, TCM syndrome score, and VAS score of the two groups were reduced, and those in the observation group were lower than those in the control group; the difference was statistically significant (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                        <c:mo>&lt;<\/c:mo>\n                        <c:mn>0.05<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>). After treatment, the quality-of-life scores of the two groups increased, and the observation group was higher than the control group; the difference was statistically significant (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.05<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>). Before treatment, there was no significant difference in serum PSA levels and f-PSA levels when comparing between the two groups of patients (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&gt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>). With the increase of treatment time, the two index levels of the two groups were gradually decreased. After 180 days of treatment, the two index levels of the two groups of patients were significantly lower than those before treatment, and the two index levels of the observation group were significantly lower than those of the control group; the difference was statistically significant (<jats:inline-formula>\n                     <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mi>P<\/i:mi>\n                        <i:mo>&lt;<\/i:mo>\n                        <i:mn>0.05<\/i:mn>\n                     <\/i:math>\n                  <\/jats:inline-formula>). After treatment, the levels of IgM and IgA in the two groups were decreased, and the level of IgG was increased. The difference between the two groups in the levels of each index before and after treatment was statistically significant (<jats:inline-formula>\n                     <k:math xmlns:k=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M6\">\n                        <k:mi>P<\/k:mi>\n                        <k:mo>&lt;<\/k:mo>\n                        <k:mn>0.05<\/k:mn>\n                     <\/k:math>\n                  <\/jats:inline-formula>), and the difference between the two groups in the levels of each index after treatment was also statistically significant (<jats:inline-formula>\n                     <m:math xmlns:m=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M7\">\n                        <m:mi>P<\/m:mi>\n                        <m:mo>&lt;<\/m:mo>\n                        <m:mn>0.05<\/m:mn>\n                     <\/m:math>\n                  <\/jats:inline-formula>). The five-year cumulative survival rate of the observation group was 69.23%, and the five-year cumulative survival rate of the control group was 46.15% (<jats:inline-formula>\n                     <o:math xmlns:o=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M8\">\n                        <o:mi>P<\/o:mi>\n                        <o:mo>&lt;<\/o:mo>\n                        <o:mn>0.05<\/o:mn>\n                     <\/o:math>\n                  <\/jats:inline-formula>). There was no statistically significant difference between the two groups in the incidence of dizziness, fatigue, and gastrointestinal reactions (<jats:inline-formula>\n                     <q:math xmlns:q=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M9\">\n                        <q:mi>P<\/q:mi>\n                        <q:mo>&gt;<\/q:mo>\n                        <q:mn>0.05<\/q:mn>\n                     <\/q:math>\n                  <\/jats:inline-formula>), but the difference in the incidence of dysuria as well as dysuria and hematuria was statistically significant (<jats:inline-formula>\n                     <s:math xmlns:s=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M10\">\n                        <s:mi>P<\/s:mi>\n                        <s:mo>&lt;<\/s:mo>\n                        <s:mn>0.05<\/s:mn>\n                     <\/s:math>\n                  <\/jats:inline-formula>). Conclusion. Jiawei Danggui Beimu Kushen pills are effective in treating prostate cancer, which can effectively reduce the patients\u2019 IPSS score and TCM syndrome scores, relieve the pain, and improve the quality of life of patients. They also have a potential role in regulating serum PSA levels, clearing tumor lesions, reducing postoperative complications, and improving related symptoms.<\/jats:p>","DOI":"10.1155\/2021\/1036068","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T22:20:08Z","timestamp":1637619608000},"page":"1-7","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Effects of Jiawei Danggui Beimu Kushen Pills in the Treatment of Prostate Cancer and Their Influence on the Expression of Serum Prostate Specific Antigen"],"prefix":"10.1155","volume":"2021","author":[{"given":"Haiyang","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Urology Surgery, The People\u2019s Hospital of Guangrao, Dongying 257300, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery, The People\u2019s Hospital of Guangrao, Dongying 257300, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-3678","authenticated-orcid":true,"given":"Guangwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery, The People\u2019s Hospital of Guangrao, Dongying 257300, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"3","key":"1","first-page":"228","article-title":"The risk factors of prostate cancer and its prevention: a literature review","volume":"48","author":"N. R. Perdana","year":"2016","journal-title":"Acta Medica Indonesiana"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2020.1.24759"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/470592"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607529"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000017624"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86141-1"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.12.014"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2018.0496"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020218"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.14444\/2048"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00315-z"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.7150\/jca.42338"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.11.021"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3086"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051517-011947"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13512"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24395"},{"issue":"5","key":"18","first-page":"3226","article-title":"Epigenetic silencing of miR-137 induces resistance to bicalutamide by targeting TRIM24 in prostate cancer cells","volume":"11","author":"Y. Guan","year":"2019","journal-title":"American Journal of Translational Research"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X17500963"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22230"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.918520"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2971644"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-016-0268-6"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2010.180"},{"issue":"6","key":"25","first-page":"452","article-title":"Screening for prostate cancer with PSA testing: current status and future directions","volume":"25","author":"J. M. Croswell","year":"2011","journal-title":"Oncology (Williston Park, N.Y.)"}],"container-title":["Evidence-Based Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2021\/1036068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2021\/1036068.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ecam\/2021\/1036068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T22:20:14Z","timestamp":1637619614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ecam\/2021\/1036068\/"}},"subtitle":[],"editor":[{"given":"Muhammad Wasim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":25,"alternative-id":["1036068","1036068"],"URL":"https:\/\/doi.org\/10.1155\/2021\/1036068","relation":{},"ISSN":["1741-4288","1741-427X"],"issn-type":[{"value":"1741-4288","type":"electronic"},{"value":"1741-427X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,22]]}}}